2008 Technology Investment/Entrepreneurship Symposium

"Investment Opportunities in Bio/Pharma Industry"

Saturday, Oct. 18, 2008
The Doubletree Guest Suites, Boston MA
Address: 400 Soldiers Field Road, Boston, MA 02134-1893
Please enter the hotel parking garage from Storrow Drive
Parking in the garage is **free** to all attendees

Co-organized by
Chinese-American BioMedical Association (CABA)
Chinese-American IP Law Association (CAIPLA)
Overseas Chinese-American Entrepreneurs Association (OCEAN)
New England Chinese Information and Networking Association (NECINA)
American Chinese Medical Association (ACMA)

Symposium Themes:
- *What are investors on the lookout for: the right people and smart business strategies;*
- *Where to find your startup money: venture capital vs. angel funds;*
- *Legal hurdles facing biotech/pharma start-up companies;*
- *Building value through cross-border partnerships;*
- *Successful Biotech entrepreneur stories.*

Registration (12:00 PM – 1:00 PM)

Symposium (1:00 PM - 6:00 PM)

- **Investor Panel (1:00 PM - 2:15 PM)**

Moderator: Henry Gu, Ph.D., Attorney, WilmerHale LLP (CAIPLA)
Panelists:
Charlie Cameron, Managing Director, Hub Angels
Steve Knight, Ph.D., Managing Partner, Fidelity BioScience
James Li, M.D., Partner, Kleiner Perkins Caufield & Byers

- **Legal/IP Panel (2:15 PM – 3:30 PM)**

Moderator: Philip Zhang, Ph.D., Esq., Special Counsel, Cooley Godward Kronish LLP (CAIPLA)
Panelists:
Patrick Mitchell, Esq., Partner, Cooley Godward Kronish LLP
Yang Xu, Ph.D., Esq., ArQule, Inc.
John Prince, Ph.D., Esq., Senior Patent Counsel, Novartis

- **PM Break** (Coffee and Cookies) (3:30 PM to 4:00 PM)

- **Entrepreneurship (4:00 PM – 6:00 PM)**

Session chairs (introduce speakers): Zhao-Kui Wan, Ph.D.; Wendy (Weiyi) Zhang, Ph.D., (CABA)
Speakers:
Shuqi Chen, Ph.D., Chairman & CEO, IQuum, Inc.
Bruno Tse, Ph.D., MBA, Vice President of Business Development, PepTech Corp.
Zhuang Su, Ph.D., President, S&T Global, Inc.

Ray Yin, Ph.D., President and CTO of ANP technologies Inc
Tim Wu, M.D., President, VasoTech, Inc.
Panel discussion moderator: Jun Han, Ph.D. (CABA)

Networking Reception (wine/beer & Hors d'Oeuvres) (6:00 PM – 7:00 PM)

Tickets available at the registration table at no extra charge

Dinner (7:00 PM - 9:30PM)

Host: Yihan Wang, Ph.D., Junjun Wu, Ph.D., Shiwen Lin, Ph.D. (CABA)
Keynote Speaker: Dr. Roger Tung, CEO and President, Concert Pharmaceuticals

Dinner tickets available (limited) for purchase at the registration table

Event Steering Committee

Chair: Zhiyong Yang, Ph.D., Wyeth Research, zyyang02@yahoo.com (CABA)
Co-Chair: Philip Zhang, Ph.D., Special Counsel, Cooley Godward Kronish LLP, pzhang@cooley.com (CAIPLA)

Organizing Committee

Zhao-Kui Wan, Ph.D., Wyeth Research, zwan@wyeth.com (CABA)
Liping Zhou, Ph.D., Novartis Inst. of BioMedical Research, Lipingx.Zhou@novartis.com (CABA)
Weiyi (Wendy) Zhang, Ph. D., EMD Serono, Inc., weiyi9825@yahoo.com (CABA)
Qinglin Che, Ph. D., Syntha Pharmaceuticals, Inc., allen.che@gmail.com (CABA)
Yihan Wang, Ph. D. ARIAD Pharmaceuticals, Inc., yihanw@yahoo.com (CABA)
Junjun Wu, Ph. D. Wyeth Research, junjun_wu_1@yahoo.com (CABA)
Yongzhong Wang, Ph. D. Genzyme Corp., Yongzhong@gmail.com (CABA & NECINA)
Yang Xu, Ph.D., Chief IP Counsel, ArQule, Inc., (CAIPLA)
Henry H. Gu, Attorney, WilmerHale LLP, Henry.Gu@wilmerhale.com (CAIPLA)
Michelle Deng, Ph.D., Patent Counsel, Genzyme Corp. (CAIPLA)
Zhuang Su, S&T Global Inc., Suzhuang@yahoo.com (OCEAN)
Tianqi Wang, tianqi_wang@housecenter.com (OCEAN)
Jerry Zhu, M. D., Harvard Medical School, zzhu@partners.org (ACMA)

Admission:

Symposium: CABA, CAIPLA, OCEAN, NECINA, ACMA members: FREE
Non-members: $20
Dinner: $25

Biosketches of Speakers/Abstracts of Presentations

- **Shuqi Chen, Ph.D.** is the President, CEO and Chairman of the Board of IQuum, Inc.. He is the founder of IQuum, and a former Harvard faculty member. IQuum's intellectual property is based on his vision and innovative approach to biological sample processing and testing that has been in development since 1994. Dr. Chen has a Ph.D. in Medicine, an M.S. in Biophysics and a B.S. in Theoretical Physics. He has received many national awards from China in recognition of his accomplishments. Among them are the National Outstanding Achievement for Technology Development, 1988; Advanced Science and

Technology Prize, 1986; National Great Achievement in Science and Technology, 1984. Dr. Chen brings to IQuum a wide assortment of disciplines as well as industrial and management experience. He has a proven record of overcoming many challenges using innovative means in both academia and industry. Dr. Chen has successfully developed medical devices for commercialization during his twenty years in blood research and medical device development.

Title of presentation: Vision, Technology, Money and People: Four Key Components in Building a Biotech Company

- **Bruno Tse, Ph.D., MBA** currently serves as the Vice President of Business Development for PepTech Corporation, heading the business development, corporate strategies and sales & marketing efforts of PepTech. Prior to this position, Bruno had played important roles in business development for several start-ups, including Amicus Therapeutics. Bruno had also served as a Research Fellow at Merck where he completed a total synthesis of (-)-galbonolide B, a natural antifungal agent, by himself. He is a co-inventor of over ten issued patents, covering the discoveries of novel therapeutics in infectious diseases and cholesterol regulation. He earned his Ph.D. in chemistry at Harvard where he was awarded Robert Burns Woodward Prize, and holds an M.B.A. from the Wharton School of Business. He is also a registered patent agent and a four-time ironman triathlete.

Title of Presentation: The Keys to Success for a Chemistry Service Company

Abstract: The business model of a service company is very different from that of a biotech/pharma company. In this presentation, Dr. Tse will speak about the current trends and general landscape of the chemistry CRO industry, with a focus on the Chinese CRO segment, and will use PepTech Corporation as a case study to speak about the key elements to run a successful service company.

- **Zhuang Su, Ph.D.** is the founder and president of S & T Global, and is currently working on small molecular drug discovery. He obtained his Ph.D. in organic chemistry from the Beijing Institute of Technology in 1989. He completed his postdoctoral research on the complicated natural product total synthesis at the Institute of Organic Chemistry, the University of Basel, Switzerland, and at the Department of Chemistry, the Ohio State University. His research at the Massachusetts Institute of Technology (MIT) led to the discovery of a molecular target of angiogenesis inhibitors. He also worked at the Immunology Department, Preclinical Research of the former Sandoz pharmaceutical (now Novartis) on the novel drug R & D.

Title of presentation: Doing drug discovery in a small company

Abstract: Drug discovery is a process in which drugs are discovered and/or designed. The process of drug discovery involves the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Once a compound has shown its value in these tests, it will begin the process of drug development prior to clinical trials. Despite advances in technology and understanding of biological systems, drug discovery is still a long process with a low rate of success. In addition, it requires a large funding support. In this discussion, Dr. Zhuang Su will talk about his own drug discovery experience in his small company with very limited funding in the anti-viral field.

- **Ray Yin, Ph.D.** is the founder and Chief Executive Officer of ANP Technologies, Inc. in Newark, Delaware (www.anptinc.com). ANP Technologies' mission is to develop cutting-edge technology platforms at the nano/bio interface, and to apply them in market sectors such as biodefense/homeland security, medical diagnostics, drug discovery, and protein therapeutics. Prior to founding ANP, Dr. Yin was the program manager for the nanobiotechnology program at the U. S. Army Research Laboratory (ARL). During this period, Dr. Yin successfully directed a number of basic research and rapid prototyping programs in the chemical and biological defense area, leading to his receiving the U. S. Army R&D

Achievement Award in 1999, 2000, and 2001. Dr. Yin was a scientific advisor to a variety of DoD programs and committees including DARPA, the Joint Service Agent Water Monitor program (JSAWM), the U.S. Army Edgewood Chemical and Biological Center (ECBC), the U.S. Army Research Office (ARO), the Office of Naval Research (ONR), the Air Force Office of Scientific Research (AFOSR), DoD National Nanotechnology Initiative (NNI) program, the U.S. Army Center for Environmental Health Research (CEHR), and the U.S. Army Medical Research Institute for Chemical Defense (MRICD). Prior to his ARL career, Dr. Yin was instrumental in developing, marketing, and licensing a number of nanomaterial-based technologies to a variety of industrial partners while working in the private sector. This includes the licensing of a key nanomaterial-based immunoassay technology currently used for the detection of various cardiac markers. Dr. Yin has published over 40 papers and holds 12 U. S. patents. Dr. Yin received his Ph.D. in chemistry from the University of Southern California, and his B.S. in chemistry from Nankai University of China.

Title of Presentation: Nanotechnology Start-up: A Unique Path to Commercialization

Abstract: Obtaining funding through traditional means (i.e., bank loans, angel investors, or traditional venture capital firms) can be a daunting task for first-time entrepreneurs. Very often, it is impossible to secure such funding due to any number of reasons – from being an "unknown factor" to venture firms, a bad credit risk to banks, or simply not being able to find the right "partner", who understands your idea and shares your vision of the product for commercialization. In contrast to such traditional funding means, alternative funding sources including the Federal and State Government agencies have become a very attractive option for high-tech start-ups. In this talk, Dr. Ray Yin will discuss the pros and cons of these funding options as well as share his own experiences in starting and organically growing a Nanobiotechnology-based company, ANP Technologies, Inc. through alternative funding sources. In addition, Dr. Yin will also illustrate how ANP Technologies was able to expand its nanotechnology platform from the biodefense arena into commercial applications including drug discovery, medical diagnostics, and protein drug delivery.

- **Tim Wu, M.D.** is currently the President and CEO of VasoTech, Inc. -- a startup biomedical company dedicated into implantable device development and manufacturing. Prior to VasoTech, Tim Wu was the Research Director at Biomedical Research Models Company at Worcester of Massachusetts, in charge of research and development and contract services for seven years. Tim Wu graduated from Tongji Medical University (Wuhan, China) with medical doctor degree in 1988 and had five years of extensive postdoctoral training at Harvard Medical School. Tim Wu has been awarded nearly three millions dollar government grant money during past several years and also has served NIH as grant reviewer in the study section of Biomedical Engineering for three consecutive years since 2004.

Title of Presenataion: Startup Biotech Company with Government Money

Abstract: Funding is always the first issue for an entrepreneur to start a new business. It is particularly critical for high risk biotech startup companies. Most entrepreneurs first turn to Angle or Venture Capital, which are harder and harder to get in current global financial crisis situation. However, government (both federal and local) has substantial amount of money available for high-tech startups. The details of how to get government money will be discussed during the meeting.

- **Roger Tung, Ph.D.**: Roger Tung is the scientific co-founder, president, and CEO of Concert Pharmaceuticals. He has over 20 years of experience in the biotech/pharma industry at institutions including Squibb, Merck, Vertex (where he was a founding scientist), as an independent consultant, and at Concert. In 2005, as an unaffiliated individual, Roger conceived and filed a series of patent applications detailing the use of deuterium to create differentiated and improved drugs. Those applications formed the basis for Concert Pharmaceuticals, which was founded in April 2006. Concert has since raised > $95M to develop this deuterium chemistry technology and will undertake clinical evaluation of its first development candidate in 2008. Previously, as an R&D executive, Roger oversaw the discovery of clinical candidates for HIV and HCV infection, inflammation, pain, sickle cell anemia, and cystic fibrosis. He was co-inventor of the marketed drugs Agenerase® and Lexiva® and served as co-development head of Agenerase® through

its US and EMEA approvals. Roger holds a Ph.D. from the University of Wisconsin-Madison in pharmaceutical chemistry and a B.A. from Reed College. He has been granted 40 US patents and has authored approximately 100 publications, book chapters, and posters. Roger has spoken widely in the US and abroad on a range of topics relating to pharmaceutical discovery and development.

Title of of presentation: TBD

For conference updates, please visit: www.cabaweb.org

For Map and driving directions, please see below,

http://doubletree1.hilton.com/en_US/dt/hotel/BOSSBDT/index.do

*Please enter the hotel parking garage from Storrow Drive. Parking is free.

Sponsors:


Cooley
GODWARD KRONISH LLP


FIDELITY BIOSCIENCES


ANP Tech


Pfizer


SYNTA
PHARMACEUTICALS®


Sundia


DiscoveRx


CHEMPARTNER
SHANGHAI CHEMPARTNER


Luknova


PeptTech